News | February 17, 2025
Glenmark Pharma reports Q3 FY25 PAT at Rs. 348 Cr
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Offers affordable, high-quality solutions for diabetes care
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
Subscribe To Our Newsletter & Stay Updated
